• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players - Product Image

Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

  • Published: April 2013
  • Region: India
  • 88 Pages
  • GBI Research

FEATURED COMPANIES

  • AstraZeneca
  • Cipla
  • Dr. Reddy’s Laboratories
  • Natco Pharma
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research, ""Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players"", which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin's Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline.

The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations.

The limitations of the current READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Oncology Therapeutics Market in India – Introduction

3 Oncology Therapeutics Market in India – Market Overview
3.1 Population Dynamics
3.2 Cancer Registration Background in India
3.3 Most Common Cancers in India
3.4 Cancer Mortality Rate
3.5 Market Characterization and Forecasts
3.6 Annual Cost of Therapy
3.7 Treatment Usage Pattern
3.7.1 Diseased Population
3.7.2 Prescription Population
3.8 Drivers and Barriers
3.8.1 Drivers
3.8.2 Restraints

4 Oncology Therapeutics Market in India – Therapeutic Landscape
4.1 Breast Cancer
4.1.1 Disease Overview
4.1.2 Staging
4.1.3 Market Size
4.1.4 Annual Cost of Therapy
4.1.5 Treatment Usage Pattern
4.1.6 Key Marketed Products
4.1.7 Competitive Landscape
4.2 Colorectal Cancer
4.2.1 Disease Overview
4.2.2 Staging
4.2.3 Market Size
4.2.4 Annual Cost of Therapy
4.2.5 Treatment Usage Pattern
4.2.6 Key Marketed Products
4.2.7 Competitive Landscape
4.3 Prostate Cancer
4.3.1 Disease Overview
4.3.2 Staging
4.3.3 Market Size
4.3.4 Annual Cost of Therapy
4.3.5 Treatment Usage Pattern
4.3.6 Key Marketed Products
4.3.7 Competitive Landscape
4.4 Lung Cancer
4.4.1 Disease Overview
4.4.2 Staging
4.4.3 Market Size
4.4.4 Annual Cost of Therapy
4.4.5 Treatment Usage Pattern
4.4.6 Key Marketed Products
4.4.7 Competitive Landscape
4.5 Non-Hodgkin's Lymphoma
4.5.1 Disease Overview
4.5.2 Staging
4.5.3 Market Size
4.5.4 Annual Cost of Therapy
4.5.5 Treatment Usage Pattern
4.5.6 Key Marketed Products
4.5.7 Competitive Landscape

5 Oncology Therapeutics Market in India – Pipeline Analysis
5.1 Introduction
5.2 Breast Cancer
5.2.1 Introduction
5.3 Colorectal Cancer
5.3.1 Introduction
5.4 Prostate Cancer
5.4.1 Introduction
5.5 Lung Cancer
5.5.1 Introduction
5.6 Non-Hodgkin's Lymphoma
5.6.1 Introduction

6 Oncology Therapeutics Market in India – Competitive Landscape
6.1 Market Share Analysis
6.2 Competitive Profiling
6.2.2 Dr. Reddy's Laboratories
6.2.3 Natco Pharma
6.2.4 AstraZeneca
6.2.5 Cipla

7 Oncology Therapeutics Market in India – Strategic Consolidations
7.1 Introduction
7.2 Merger & Acquisition Deals
7.2.1 M&A by Year
7.3 Licensing Agreements
7.3.1 Deals by Year
7.3.2 Major Licensing Deals
7.4 Co-Development Deals
7.4.1 Deals by Year
7.4.2 Major Co-Development Deals

8 Oncology Therapeutics Market in India – Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Bibliography
8.4 Research Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Primary Research
8.4.4 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables

Table 1: Oncology Therapeutics Market, India, Incidence and Prevalence by Cancer Type, 2008
Table 2: Oncology Therapeutics Market, India, Estimated Cancer Deaths by Cancer Type, 2010
Table 3: Oncology Therapeutics Market, India, Revenue ($m), 2004–2011
Table 4: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 5: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 6: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 7: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 8: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 9: Breast Cancer Therapeutics Market, India, Staging Description, 2012
Table 10: Breast Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 11: Breast Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 12: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 13: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 14: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 15: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 16: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 17: Breast Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 18: Colorectal Cancer Therapeutics Market, India, Staging Description, 2012
Table 19: Colorectal Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 20: Colorectal Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 21: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 22: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 23: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 24: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 25: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 26: Colorectal Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 27: Prostate Cancer Therapeutics Market, India, Staging Description, 2012
Table 28: Prostate Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 29: Prostate Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 30: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 31: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 32: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 33: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 34: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 35: Prostate Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 36: Lung Cancer Therapeutics Market, India, Staging Description, 2012
Table 37: Lung Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 38: Lung Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 39: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 40: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 41: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 42: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 43: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 44: Lung Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 45: Non-Hodgkin's Lymphoma Therapeutics Market, India, Staging Description, 2012
Table 46: Non-Hodgkin's Lymphoma Therapeutics Market in India, Revenue ($m), 2004–2011
Table 47: Non-Hodgkin's Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 48: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 49: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 50: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 51: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 52: Non-Hodgkin's Lymphoma Therapeutics Market, India, Key Marketed Products, 2011
Table 53: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase, 2012
Table 54: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I, 2012
Table 55: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I/II, 2012
Table 56: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase II, 2012
Table 57: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase III, 2012
Table 58: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase, 2012
Table 59: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase I/II, 2012
Table 60: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II, 2012
Table 61: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II/III, 2012
Table 62: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase III, 2012
Table 63: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase, 2012
Table 64: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase II, 2012
Table 65: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase III, 2012
Table 66: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase, 2012
Table 67: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase I/II, 2012
Table 68: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase II, 2012
Table 69: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase III, 2012
Table 70: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline by Phase, 2012
Table 71: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline, Phase II/III, 2012
Table 72: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline, Phase III, 2012

1.2 List of Figures

Figure 1: Oncology Therapeutics Market, India, Population Growth Forecast (million), 2001–2025
Figure 2: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 3: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 4: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 5: Oncology Therapeutics Market, India, Key Drivers and Barriers, 2012
Figure 6: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 7: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 8: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 9: Breast Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011
Figure 10: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 11: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 12: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 13: Colorectal Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011
Figure 14: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 15: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 16: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 17: Prostate Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 18: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 19: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 20: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 21: Lung Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 22: Non-Hodgkin's Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 23: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 24: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 25: Non-Hodgkin's Lymphoma Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 26: Oncology Therapeutics Market, India, R&D Pipeline by Indication (%), 2012
Figure 27: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase (%), 2012
Figure 28: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase (%), 2012
Figure 29: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase (%), 2012
Figure 30: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase (%), 2012
Figure 31: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline by Phase (%), 2012
Figure 32: Oncology Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 33: Oncology Therapeutics Market, India, Hoffmann-La Roche, SWOT Analysis, 2011
Figure 34: Oncology Therapeutics Market, India, Dr. Reddy's Laboratories, SWOT Analysis, 2011
Figure 35: Oncology Therapeutics Market, India, Natco Pharma, SWOT Analysis, 2011
Figure 36: Oncology Therapeutics Market, India, AstraZeneca, SWOT Analysis, 2011
Figure 37: Oncology Therapeutics Market, India, Cipla, SWOT Analysis, 2011
Figure 38: Oncology Therapeutics Market, India, Strategic Consolidation, Deals by Type, 2008–2012
Figure 39: Oncology Therapeutics Market, India, M&A by Year, 2008–2012
Figure 40: Oncology Therapeutics Market, India, Licensing Agreements by Year, 2008–2012
Figure 41: Oncology Therapeutics Market, India, Co-Development Deals by Year, 2008–2012

- AstraZeneca
- Cipla
- Dr. Reddy’s Laboratories
- Natco Pharma

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos